Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd., a foreign private issuer, has announced its commitment to adhere to HIPAA regulations, signaling an enhancement in patient data protection and compliance standards. The move comes as part of the company’s regulatory obligations outlined in its latest filing with the SEC for September 2024.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
